Immunis

Irvine, CA · Founded 2019 · Privately Held (backing)

Developer of stem cell-derived therapy designed to treat age and disease-related immune decline. Immunis is based in Irvine, CA and was founded in 2019. Its last known valuation is $75 million. It has raised $37 million across 2 recorded rounds; the latest was a $12 million early-stage round in May 2026.

Last price · $/share
—
Implied valuation
$75.0M
Total raised
$37.0M
Last round
Early Stage VC
May 2026
How much has Immunis raised?
$37.0Macross 2 recorded rounds · Jun 2024 – May 2026

Most recently, Immunis raised $12.0M in its Early Stage VC (May 2026).

Free account
More of Immunis with a free account
  • ·The complete investor list: 12 names
  • ·Watch Immunis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Immunis round by round

2 rounds
May 2026Early Stage VC$12.0MSEC filing▮
12 investors participated
Jun 2024Early Stage VC$20.4MSEC filing▮
27 investors participated

How much has Immunis raised?

Immunis has raised $37 million across 2 recorded rounds since 2024. The largest was a $20.4 million early-stage round in Jun 2024; the most recent was a $12 million early-stage round in May 2026.

Immunis has filed 2 Form Ds with the SEC, most recently in Oct 2024 ($20.4 million sold to 27 investors).

Immunis investors

12 investors are on record for Immunis, including BOLD Capital Partners, Elevation Capital (Canada), Angel Star Ventures and Continuum Health Ventures. The early-stage round in May 2026 drew 12 investors.

For fundraisers
Raising for a company like Immunis?

12 investors have backed Immunis.

See all 12 investors →

Frequently asked about Immunis

How much has Immunis raised?
Immunis has raised $37.0M in total across 2 recorded funding rounds.
When was Immunis's last funding round?
Immunis's most recent recorded round was Early Stage VC in May 2026, raising $12.0M.